

University of Groningen

## Oncogenic variants guiding treatment in thoracic malignancies

Meng, Pei

DOI:  
[10.33612/diss.160074057](https://doi.org/10.33612/diss.160074057)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2021

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*  
Meng, P. (2021). *Oncogenic variants guiding treatment in thoracic malignancies*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.160074057>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# Oncogenic variants guiding treatment in thoracic malignancies

---

Pei Meng

Meng, P

**Oncogenic variants guiding treatment in thoracic malignancies**

Thesis, University of Groningen, Groningen, The Netherlands

Printing of this thesis was financially supported by the university of Groningen, the Graduate School of Medical Sciences, University of Groningen.

**Cover:** Pei Meng

**Layout:** Pei Meng

**Printed by:** Gildeprint | [www.gildeprint.nl](http://www.gildeprint.nl)

**Copyright © 2021, P. Meng, The Netherlands**

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanically, by photocopying, recording, or otherwise without prior written permission of the author.



university of  
 groningen

# **Oncogenic variants guiding treatment in thoracic malignancies**

**PhD thesis**

to obtain the degree of PhD at the  
University of Groningen  
on the authority of the  
Rector Magnificus Prof. C. Wijnenga  
and in accordance with  
the decision by the College of Deans.

This thesis will be defended in public on

Monday 15 March 2021 at 11.00 hours

by

**Pei Meng**

born on 5 September 1990  
in Hunan, China

## **Supervisors**

Prof. J.H.M. van den Berg  
Prof. H.J.M. Groen

## **Co-supervisors**

Dr. K. Kok  
Dr. A.J. van der Wekken

## **Assessment Committee**

Prof. H.A.M. Kerstjens  
Prof. M.R. Groves  
Prof. B. Sorensen

# **Paranymphs**

Yichen Liu

Weiting Li



# Contents

<b>Chapter 1</b>	Introduction and scope of this thesis	9
<b>Chapter 2</b>	An all-in-one transcriptome-based assay to identify therapy-guiding genomic aberrations in non-small cell lung cancer patients ( <i>Cancers</i> . 2020 Oct; 12(10): 2843)	29
<b>Chapter 3</b>	Detecting therapy-guiding RNA aberrations in platelets of non-small cell lung cancer patients ( <i>medRxiv</i> . 2021 Jan 26)	61
<b>Chapter 4</b>	Concurrent oncogenic gene mutations in <i>BRAF</i> p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib	81
<b>Chapter 5</b>	Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small cell lung cancer patients with an osimertinib-induced <i>BRAF</i> V600E mutation ( <i>Lung Cancer</i> . 2020 Aug; 146: 358-361)	97
<b>Chapter 6</b>	Clinical value of <i>EGFR</i> copy number gain determined by amplicon-based targeted next generation sequencing in <i>EGFR</i> mutated NSCLC patients (In revision)	105
<b>Chapter 7</b>	Targeted sequencing of circulating cell-free DNA in stage II-III resectable esophageal squamous cell carcinoma patients ( <i>BMC Cancer</i> . 2019 Aug 20; 19(1): 818)	125
<b>Chapter 8</b>	Summary, discussion and future perspectives	155
<b>Appendices</b>	Dutch summary (Nederlandse samenvatting)	169
	Acknowledgements	173



